维普中文期刊产品整合服务
7篇 您的检索式:作者名="BOUSCARY M L"
    题名 作者 年代 出处 被引量
1A non-randomised dose-escalating phase Ⅱ study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Mye1odysplasies 显示文摘Bouscary D Legros L Tulliez M 2005British Journal of Haematology2005,131,5:1
2A non-randomized dose-escelgting phase II study of thalidomide for the treatment of patients with low risk myelodysplastic syndromes:the Thal-SMD-2000 trial of the Group Francais des Mye Iodysplasies显示文摘Bouscary D legros L Tuiliez M 2005Br J Haematol2005,131,:1
3Discordance between physicians' estimations and breast cancer patients' self-assessment of side-effects of chemotherapy: an issue for quality of care 显示文摘MACQUART-MOULIN G VIENS P BOUSCARY M L 1997Br J Cancer1997,76,:1
4Activity of the caspase-3/CPP32 enzyme is increased in‘early stage ' myelodysplastic syndromes with excessive apoptosis,but caspase inhibition does not enhance colony formation in vitro显示文摘Bouscary D Chen Y L Guesnu M 2000Exp Hematol2000,28,7:1
5A non-randomised doseescalating phase Ⅱ study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: The Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies 显示文摘Bouscary D Legros L Tulliez M 2005Br J Haematol2005,131,609:1
6Activity of the caspase-3/CPP32 enzyme is increased in 'early stage' myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro显示文摘Bouscary D Chen Y L Guesnu M 2000Exp Hematol2000,28,:1
7Anonrandomised dose - escalatingphase II study of thalidomide for the treatment of patients with low- risk myelodysplastics yndromes:the Thai - SMD2000 trim of the Group Francaisdes Myelodysplasies 显示文摘Bouscary D Legros L Tulliez M 2010Sr JHaematol2010,131,12:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费